Clinical Utility of TRBC1 Addition in Multiparametric Flow Cytometry for T Cell Lymphoma DiagnosisPicone, Gorrese, Bertolini
et alTransl Med UniSa (2024) 26 (1), 93-98
Abstract: Diagnosis of T cell lymphoproliferative disorders requires one or multiple immunophenotypic aberrations, histological tissue structure or composition modifications, and T cell clonality demonstration. Here, we present two T cell lymphoma cases, where TCR clonality was evaluated using the TRBC1 monoclonal antibody combined with a multi-parametric staining for an in-depth immunophenotype of physiological and pathological T cell populations. In the first case, this monoclonal antibody allowed exclusion of reactive lymphoproliferations, while in the second case, it was conclusive for identification of Sezary syndrome cells. We added evidence on clinical utility of TRBC1 antibody (JOVI-1) to disclose monotypic T-cell populations, and TCR clonality evaluated by TRBC1 monoclonal antibody can be efficiently combined with a multi-parametric staining for an in-depth immunophenotype, with high versability of this monoclonal antibody in multi-parametric flow cytometry panel.© 2024 Università di Salerno.
The real-world application of T-cell receptor constant beta-1 chain antibody assay in cutaneous T-cell lymphomaPierog, Craig, Jennings
et alBr J Haematol (2025)
Abstract: Identifying aberrant T lymphocytes in peripheral blood is essential for diagnosing Sezary syndrome (SS) and is a prognostic indicator in mycosis fungoides (MF). Flow cytometry using a T-cell receptor constant beta-1 chain (TRBC1)-targeting antibody provides a refined approach for detecting T-cell clonality. We evaluated the performance of the TRBC1 antibody assay (TRBC1-aa) in 164 patients, compared to standard flow cytometry methods for assessing T-cell aberrancy, demonstrating 92.3% sensitivity and 83.5% specificity. TRBC1-aa accurately excluded clonality in 100% of benign inflammatory dermatoses and improved the detection of residual blood involvement earlier than standard flow cytometry in 66.7% of SS and 25.0% of advanced-stage MF patients on systemic therapy.© 2025 British Society for Haematology and John Wiley & Sons Ltd.
Computational free flow cytometry for Sézary cells identification and quantificationTa, Ram-Wolff, Annabi
et alJ Invest Dermatol (2025)
Abstract: Although robust, these methods rely on highly standardized procedures that encompass all steps of FC, prior characterization of normal CD4+ T-cells from healthy donors and/or CTCL patients, and the use of multiparametric panels requirements typically only supported by reference centers. In this context, simplified FC strategy has been proposed, utilizing computationally enhanced data files (Seheult et al. 2024). However, the remarkable heterogeneity of SS, particularly the variability in the phenotype of SCs, which can evolve over time as the disease progresses, underscores the necessity of using more specific markers for their identification. This dynamic nature of SCs, characterized by shifts in immunophenotypic expression and clonal diversity, presents a challenge for accurate diagnosis and monitoring, making the application of advanced flow cytometry techniques and computational analysis crucial in clinical practice.Copyright © 2025 The Authors. Published by Elsevier Inc. All rights reserved.
The Diagnostic Utility of TRBC1 Immunohistochemistry in Mature T-Cell LymphomasZhou, Sardana, Eren
et alMod Pathol (2025) 38 (6), 100725
Abstract: T-cell clonality assessment constitutes an essential part of the diagnostic evaluation of suspected T-cell neoplasms. Recent advances in flow cytometry-based analysis of TCR β-chain constant region 1 (TRBC1) have introduced an accurate method of assessment of T-cell clonality. Its broader applicability is constrained due to the requirement of viable cells. Furthermore, the utility of the TRBC1 antibody in tissue immunohistochemistry (IHC) has not been comprehensively addressed. Herein, we validated an IHC-based approach to assess T-cell clonality using formalin-fixed, paraffin-embedded tissue. Utilizing DeepLIIF image analysis, we quantified TRBC1 positivity among CD3-positive cells in a training cohort comprising 34 cases of α/β T-cell neoplasms and 29 cases of reactive lymphoid tissue as controls. In an independent validation cohort comprising 29 T-cell neoplasms and 20 controls, similar image quantification was conducted by a pathologist uninvolved in the analysis of the training cohort and blinded to the diagnoses. Receiver operating characteristic analysis of the training cohort established the optimal cutoff points for monotypic TRBC1 expression-79.0% or higher indicating monotypic positivity and 36.3% or lower denoting negativity. These thresholds demonstrated robust metrics in both the training (sensitivity 88.2%, specificity 93.1%, positive predictive value 93.8%, negative predictive value 87.1%) and the validation cohorts (sensitivity 93.1%, specificity 95.0%, positive predictive value 96.4%, negative predictive value 90.5%). TRBC1 IHC was correlated with flow cytometry in 52 cases, which demonstrated a strong quantitative correlation of TRBC1 positivity (r = 0.78; P <.001) and a high categoric agreement (85.9%) in classifying monotypic versus polytypic staining. Discrepancies in categorization were associated with low tumor percentages. Furthermore, multiplex immunofluorescence was performed in 15 cases for targeted quantification of TRBC1 expression in CD3-positive, PAX5-negative cells, achieving a concordance of 86.7% with IHC. In summary, TRBC1 IHC offers a reliable and practical complementary method for assessing T-cell clonality.Copyright © 2025 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights reserved.
膜杰作
Star Staining
